Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Inclusion Criteria: * Histologically or pathologically confirmed malignancy (hematologic or solid tumor) that is metastatic or unresectable and for which standard of care therapy does not exist or is no longer effective * ACT infusion prior to study enrollment (cohorts include ACT with tumor infiltrating lymphocytes \[TIL\], human leukocyte antigen \[HLA\]-class I T cell receptor \[TCR\]-engineered lymphocytes, HLA-class II TCR-engineered lymphocytes, and chimeric antigen receptor \[CAR\]-engineered T cells) * Prior ACT therapy should be completed, and residual disease documented by either radiographic progression or active disease observed on biopsy (i.e. hematologic or solid tumor malignancy must be deemed active by the treating investigator); the investigator may deem that the disease is active on the basis of a pre-treatment biopsy demonstrating viable tumor cells or clinical progression of disease (i.e. RECIST progression is not required) * Solid tumor patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>= 20 mm (\>= 2 cm) with conventional techniques or as \>= 15 mm (\>= 1.5 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam * Leukemia and non-Hodgkin's lymphoma patients must have measurable disease according to the revised response criteria …